Home › Companies › NURIX THERAPEUTICS INC. › 2024-2025

NURIX THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and NURIX THERAPEUTICS INC.’s Form 8-K, filed 2025-05-19 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
201Asset managers
1,368Fund votes
2025-05-19Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore NURIX THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by NURIX THERAPEUTICS INC.

These tallies are NURIX THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-19 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

NURIX THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-05-19
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Judith A. Reinsdorf	43,571,416	--	--	17,651,464	3,833,317	Majority: yes
Elect Director: Edward C. Saltzman	50,302,518	--	--	10,920,362	3,833,317	Majority: yes
Elect Director: Roy D. Baynes	60,821,712	--	--	401,168	3,833,317	Majority: yes

Source: NURIX THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-05-19 — read the filing on EDGAR.

How asset managers voted at the NURIX THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 201 asset managers that disclosed a NURIX THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of NURIX THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

62% fund support · no official result

FOR 62%AGAINST 38%

The 111 asset managers below cast 62% of the shares they voted on this item FOR (32,539,248 for, 20,006,828 against).

FOR: 32,539,248 (61.9%)AGAINST: 20,006,828 (38.1%)

Largest asset managers voting on “To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclo” at NURIX THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Fidelity	1,451,235	19,041,768	Against
T. Rowe Price	8,308,323	0	For
Vanguard	4,316,000	0	For
Commodore Capital LP	4,085,581	0	For
State Street	1,757,828	149	For
PICTET ASSET MANAGEMENT SA	1,621,429	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,598,027	0	For
Artisan	1,034,565	0	For
Nikko Asset Management Co., Ltd.	756,976	0	For
BESSEMER TRUST Co NATIONAL ASSOCIATION	611,868	0	For
Candriam S.C.A.	0	588,908	Against
WASATCH ADVISORS LP	569,613	0	For
WASATCH FUNDS TRUST	534,580	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	454,461	0	For
Woodline Partners LP	404,968	0	For
Point72	377,441	0	For
Victory Capital	362,962	0	For
Vestal Point Capital, LP	321,899	0	For
Dimensional	312,955	0	For
Bessemer Trust CO of Delaware, N.A.	309,450	0	For
BESSEMER TRUST CO	307,106	0	For
BESSEMER TRUST Co OF FLORIDA	307,106	0	For
Bessemer Trust Co of Nevada, National Association	307,106	0	For
Citadel	261,469	0	For
Equitable	188,858	0	For

Showing the 25 largest of 111 asset managers. See all 111 in the interactive database.

2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

99.8% fund support · no official result

FOR 99.5%

The 92 asset managers below cast 99.8% of the shares they voted on this item FOR (24,721,161 for, 31,959 against).

FOR: 24,721,161 (99.6%)AGAINST: 31,959 (0.1%)ABSTAIN: 70,765 (0.3%)NOT VOTED: 46 (0.0%)

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as dis” at NURIX THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
BlackRock	5,637,076	5,004	For
Redmile Group, LLC	4,051,927	0	For
Deep Track Capital, LP	3,452,910	0	For
Wellington	2,507,434	0	For
Soleus Capital Management, L.P.	2,368,719	0	For
ARK ETF Trust	1,538,187	0	For
Charles Schwab	1,102,513	0	For
Northern Trust	457,399	0	For
Hartford	432,350	0	For
Affinity Asset Advisors, LLC	350,055	0	For
ArrowMark Colorado Holdings LLC	314,762	0	For
Ensign Peak Advisors, Inc	300,968	0	For
PRIMECAP MANAGEMENT CO/CA/	232,000	0	For
Russell Investments	228,947	0	For
SAMLYN CAPITAL, LLC	227,228	0	For
PRIMECAP Odyssey Funds	212,000	0	For
Opaleye Management Inc.	147,327	0	For
WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST	124,100	0	For
QUANTITATIVE MASTER SERIES LLC	118,386	0	For
Integral Health Asset Management, LLC	95,925	0	For
Northwestern Mutual	95,038	0	For
John Hancock	70,384	0	For
MassMutual	65,250	0	For
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	62,109	0	For
Tema ETF Trust	59,146	0	For

Showing the 25 largest of 92 asset managers. See all 92 in the interactive database.

3. Election of Directors: Judith A. Reinsdorf

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

71% Majority: yes · of votes cast

FOR 71%WITHHELD 29%

FOR: 43,571,416WITHHELD: 17,651,464

NURIX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Judith A. Reinsdorf”): 43,571,416 for, 17,651,464 withheld, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,234,799 outstanding shares: 57% for, 23% withheld (80% of the company cast a for/withheld vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (17,785,352 for, 0 against).

FOR 64%ABSTAIN 36%

FOR: 17,785,352 (64.0%)ABSTAIN: 10,024,729 (36.0%)

Largest asset managers voting on “Election of Directors: Judith A. Reinsdorf” at NURIX THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	1,451,235	9,024,776	Abstain
Vanguard	4,107,266	0	For
BlackRock	3,890,098	0	For
T. Rowe Price	3,294,671	0	For
ARK ETF Trust	1,538,187	0	For
Charles Schwab	551,228	0	For
WASATCH FUNDS TRUST	534,580	0	For
Artisan	448,628	0	For
Hartford	432,350	0	For
PRIMECAP Odyssey Funds	212,000	0	For
State Street	209,421	188	For
Dimensional	0	206,716	Abstain
Equitable	125,538	63,320	For
Victory Capital	1,578	177,221	Abstain
TIAA	160,469	0	For
QUANTITATIVE MASTER SERIES LLC	118,386	0	For
DRIEHAUS MUTUAL FUNDS	0	114,985	Abstain
Northwestern Mutual	95,038	0	For
Lincoln Financial	51,300	38,415	For
Russell Investments	85,053	0	For
John Hancock	45,962	24,422	For
MassMutual	70,239	0	For
Tema ETF Trust	59,146	0	For
Northern Trust	0	52,576	Abstain
RBB FUND, INC.	0	52,098	Abstain

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

4. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2025.

AUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 63 asset managers below cast 99.9% of the shares they voted on this item FOR (27,804,074 for, 13 against).

FOR: 27,804,074 (100.0%)AGAINST: 13 (0.0%)ABSTAIN: 5,994 (0.0%)

Largest asset managers voting on “Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public a” at NURIX THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Fidelity	10,476,011	0	For
Vanguard	4,107,266	0	For
BlackRock	3,890,098	0	For
T. Rowe Price	3,294,671	0	For
ARK ETF Trust	1,538,187	0	For
Charles Schwab	551,228	0	For
WASATCH FUNDS TRUST	534,580	0	For
Artisan	448,628	0	For
Hartford	432,350	0	For
PRIMECAP Odyssey Funds	212,000	0	For
State Street	209,596	13	For
Dimensional	206,716	0	For
Equitable	188,858	0	For
Victory Capital	178,799	0	For
TIAA	160,469	0	For
QUANTITATIVE MASTER SERIES LLC	118,386	0	For
DRIEHAUS MUTUAL FUNDS	114,985	0	For
Northwestern Mutual	95,038	0	For
Lincoln Financial	89,715	0	For
Russell Investments	85,053	0	For
John Hancock	70,384	0	For
MassMutual	70,239	0	For
Tema ETF Trust	59,146	0	For
Northern Trust	52,576	0	For
RBB FUND, INC.	52,098	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

5. Election of Directors: Edward C. Saltzman

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD 18%

FOR: 50,302,518WITHHELD: 10,920,362

NURIX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Edward C. Saltzman”): 50,302,518 for, 10,920,362 withheld, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,234,799 outstanding shares: 66% for, 14% withheld (80% of the company cast a for/withheld vote).

The 62 asset managers below cast 100% of the shares they voted on this item FOR (18,438,796 for, 0 against).

FOR 66%ABSTAIN 34%

FOR: 18,438,796 (66.4%)ABSTAIN: 9,329,285 (33.6%)

Largest asset managers voting on “Election of Directors: Edward C. Saltzman” at NURIX THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	1,451,235	9,024,776	Abstain
Vanguard	4,107,266	0	For
BlackRock	3,890,098	0	For
T. Rowe Price	3,294,671	0	For
ARK ETF Trust	1,538,187	0	For
Charles Schwab	551,228	0	For
WASATCH FUNDS TRUST	534,580	0	For
Artisan	448,628	0	For
Hartford	432,350	0	For
PRIMECAP Odyssey Funds	212,000	0	For
State Street	209,609	0	For
Dimensional	0	206,716	Abstain
Equitable	125,538	63,320	For
Victory Capital	178,799	0	For
TIAA	160,469	0	For
QUANTITATIVE MASTER SERIES LLC	118,386	0	For
DRIEHAUS MUTUAL FUNDS	114,985	0	For
Northwestern Mutual	95,038	0	For
Lincoln Financial	88,436	1,279	For
Russell Investments	85,053	0	For
John Hancock	70,384	0	For
MassMutual	70,239	0	For
Tema ETF Trust	59,146	0	For
Northern Trust	52,576	0	For
RBB FUND, INC.	52,098	0	For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

6. Election of Directors: Roy D. Baynes

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%

FOR: 60,821,712WITHHELD: 401,168

NURIX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Roy D. Baynes”): 60,821,712 for, 401,168 withheld, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,234,799 outstanding shares: 80% for, 0.6% withheld (80% of the company cast a for/withheld vote).

The 62 asset managers below cast 100% of the shares they voted on this item FOR (27,534,237 for, 0 against).

FOR 99.1%

FOR: 27,534,237 (99.2%)ABSTAIN: 233,844 (0.8%)

Largest asset managers voting on “Election of Directors: Roy D. Baynes” at NURIX THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	10,476,011	0	For
Vanguard	4,107,266	0	For
BlackRock	3,890,098	0	For
T. Rowe Price	3,294,671	0	For
ARK ETF Trust	1,538,187	0	For
Charles Schwab	551,228	0	For
WASATCH FUNDS TRUST	534,580	0	For
Artisan	448,628	0	For
Hartford	432,350	0	For
PRIMECAP Odyssey Funds	212,000	0	For
State Street	209,609	0	For
Dimensional	0	206,716	Abstain
Equitable	188,858	0	For
Victory Capital	178,799	0	For
TIAA	160,469	0	For
QUANTITATIVE MASTER SERIES LLC	118,386	0	For
DRIEHAUS MUTUAL FUNDS	114,985	0	For
Northwestern Mutual	95,038	0	For
Lincoln Financial	88,436	1,279	For
Russell Investments	85,053	0	For
John Hancock	70,384	0	For
MassMutual	70,239	0	For
Tema ETF Trust	59,146	0	For
Northern Trust	52,576	0	For
RBB FUND, INC.	52,098	0	For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

81% fund support · no official result

FOR 81%AGAINST 19%

The 3 asset managers below cast 81% of the shares they voted on this item FOR (128,809 for, 29,657 against).

FOR: 128,809 (81.3%)AGAINST: 29,657 (18.7%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at NURIX THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Jasper Ridge Partners, L.P.	95,711	0	For
JPMorgan	33,098	0	For
Desjardins Global Asset Management Inc.	0	29,657	Against

Largest NURIX THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of NURIX THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 76,234,799 shares outstanding at the time of that meeting.

Top NURIX THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Fidelity	26.88%
2	T. Rowe Price	10.90%
3	Vanguard	5.66%
4	Commodore Capital LP	5.36%
5	State Street	2.31%
6	PICTET ASSET MANAGEMENT SA	2.13%
7	GEODE CAPITAL MANAGEMENT, LLC	2.10%
8	Artisan	1.36%
9	Nikko Asset Management Co., Ltd.	0.99%
10	BESSEMER TRUST Co NATIONAL ASSOCIATION	0.80%

Reported NURIX THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

NURIX THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Redmile Group, LLC	14.03%	13G
FMR (Fidelity)	13.55%	13F
FMR LLC	13.52%	DEF14A
BlackRock	10.48%	13F
Baker Bros. Advisors LP	8.86%	DEF14A
Vestal Point Capital, LP	8.53%	13G
Deep Track Capital, LP	8.32%	13G
Vanguard Group	5.79%	13F
Commodore Capital LP	5.05%	DEF14A
Arthur T. Sands, M.D., Ph.D.	4.74%	DEF14A

Percentages above are of 76,234,799 shares outstanding, as reported by NURIX THERAPEUTICS INC. on its Form 10-Q dated 2025-02-28 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NURIX THERAPEUTICS INC.’s 10-Q dated 2025-02-28. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At NURIX THERAPEUTICS INC.'s shareholder meeting held 2025-05-19, in the 2024-2025 proxy season, 201 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,368 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. NURIX THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, a non-binding advisory basis, the compensation of the Company's named executive… — the reporting funds cast 62% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

NURIX THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.